Interleukin-2: Evaluation of Routes of Administration and Current Delivery Systems in Cancer Therapy

被引:41
作者
Shaker, Mohamed A. [1 ]
Younes, Husam M. [1 ,2 ]
机构
[1] Mem Univ Newfoundland, Sch Pharm, St John, NF A1B 3V6, Canada
[2] Qatar Univ, Dept Pharmaceut Sci, Coll Pharm, Doha, Qatar
关键词
cancer; controlled release; pharmacokinetics; physicochemical properties; polymeric drug delivery systems; protein delivery; RENAL-CELL CARCINOMA; ACTIVATED KILLER-CELLS; RECOMBINANT HUMAN INTERLEUKIN-2; LOCAL IL-2 THERAPY; MALIGNANT PLEURAL MESOTHELIOMA; PHASE-II TRIAL; GENE-THERAPY; CONTROLLED-RELEASE; IN-VIVO; PULMONARY METASTASES;
D O I
10.1002/jps.21596
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Despite the fact that different administration routes and delivery systems have been used for interleukin-2 (IL-2) delivery, little has been reported regarding the most efficient strategies used to deliver IL-2 in a nontoxic, efficient, stable and safe manner. Systemic IL-2 administration has always been associated with rapid clearance and severe toxicity as a result of its narrow therapeutic index. Loco-regional IL-2 delivery, however, is used to localize IL-2 actions and activities into the vicinity of tumors and can result in an improved therapeutic outcome with much less side effects or toxicity. The purpose of this review is to report on the different properties and aspects of IL-2, including its mechanism of action, physicochemical properties, and structure which have an impact on the activity, stability and formulation of IL-2 dosage forms and delivery systems. In addition, advantages and limitations of the currently available techniques and strategies to deliver IL-2 will also be covered. (C) 2008 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 98:2268-2298, 2009
引用
收藏
页码:2268 / 2298
页数:31
相关论文
共 201 条
  • [1] TRANSDUCTION OF HUMAN-MELANOMA CELLS WITH INTERLEUKIN-2 GENE REDUCES TUMORIGENICITY AND ENHANCES HOST ANTITUMOR IMMUNITY - A NUDE-MOUSE MODEL
    ABDELWAHAB, Z
    LI, WP
    OSANTO, S
    DARROW, TL
    HESSLING, J
    VERVAERT, CE
    BURRASCANO, M
    BARBER, J
    SEIGLER, HF
    [J]. CELLULAR IMMUNOLOGY, 1994, 159 (01) : 26 - 39
  • [2] Mechanism of action of interleukin-2 (IL-2)-Bax, an apoptosis-inducing chimaeric protein targeted against cells expressing the IL-2 receptor
    Aqeilan, R
    Kedar, R
    Ben-Yehudah, A
    Lorberboum-Galski, H
    [J]. BIOCHEMICAL JOURNAL, 2003, 370 : 129 - 140
  • [3] Binding of small molecules to an adaptive protein-protein interface
    Arkin, MR
    Randal, M
    DeLano, WL
    Hyde, J
    Luong, TN
    Oslob, JD
    Raphael, DR
    Taylor, L
    Wang, J
    McDowell, RS
    Wells, JA
    Braisted, AC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) : 1603 - 1608
  • [4] Astoul P, 1998, CANCER, V83, P2099, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO
  • [5] 2-3
  • [6] The incorporation and release of bovine serum albumin from poly(beta-hydroxybutyrate-hydroxyvalerate) microspheres
    Atkins, TW
    Peacock, SJ
    [J]. JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 1996, 7 (12) : 1065 - 1073
  • [7] Interleukin 2: from immunostimulation to immunoregulation and back again
    Bachmann, Martin F.
    Oxenius, Annette
    [J]. EMBO REPORTS, 2007, 8 (12) : 1142 - 1148
  • [8] Differential role of IL-2R signaling for CD8+ T cell responses in acute and chronic viral infections
    Bachmann, Martin F.
    Wolint, Petra
    Walton, Senta
    Schwarz, Katrin
    Oxenius, Annette
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2007, 37 (06) : 1502 - 1512
  • [9] The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy
    Baselmans, AHC
    Koten, JW
    Battermann, JJ
    Van Dijk, JE
    Den Otter, W
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (09) : 492 - 498
  • [10] UNRAVELING THE STRUCTURE OF IL-2
    BAZAN, JF
    [J]. SCIENCE, 1992, 257 (5068) : 410 - 412